In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
|Articles|June 20, 2023
Supplements and Featured Publications
- Integrated Multidisciplinary Limb Salvage Programs: Reducing Amputations Among Patients With Peripheral Artery Disease
Advocate Health Care Limb Salvage Center of Excellence at Advocate Trinity Hospital
Advertisement
In this AJMC® Profiles in Care, key stakeholders affiliated with Advocate Health Care in Southeast Chicago, Illinois share best practices for development of a limb salvage program for people at high risk of limb amputation due to peripheral artery disease.
Articles in this issue
almost 3 years ago
Inova Health System Center of ExcellenceAdvertisement
Related to this article
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
5